Cytomegalovirus Infections: all 362 studies
Page 2 of 4. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.
- A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched ControlsCompletedNCT01663740Phase 4Results posted
- Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing LossCompletedNCT01649869Phase 2Results posted
- Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT01646645Phase 2Results posted
- Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant RecipientsCompletedNCT01611974Phase 2Results posted
- Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) InfectionCompletedNCT01602614Results posted
- CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")CompletedNCT01552369Phase 4Results posted
- Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus InfectionCompletedNCT01509404Phase 4Results posted
- A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant RecipientsCompletedNCT01376804Phase 4Results posted
- A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)CompletedNCT01376778Phase 3Results posted
- Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) VaccineCompletedNCT01357915Not applicableResults posted
- Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to FoetusCompletedNCT01251744Not applicableResults posted
- Evaluation of the Artus® CMV PCR TestCompletedNCT01034709Results posted
- Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant RecipientsCompletedNCT00942305Phase 2Results posted
- Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant RecipientsCompletedNCT00497796Phase 3Results posted
- Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV InfectionsCompletedNCT00466817Phase 3Results posted
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant RecipientsCompletedNCT00411645Phase 3Results posted
- A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.CompletedNCT00377741Phase 1Results posted
- A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal TransplantationCompletedNCT00372229Phase 3Results posted
- Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell DonorsCompletedNCT00353977Phase 2Results posted
- IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft RecipientsCompletedNCT00294515Phase 3Results posted
- Valganciclovir to Reduce T Cell Activation in HIV InfectionCompletedNCT00264290Phase 4Results posted
- Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung TransplantationCompletedNCT00227370Phase 3Results posted
- Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative WomenTerminatedNCT00201448Phase 2/3Results posted
- A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant RecipientsCompletedNCT00090766Phase 2/3Results posted
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant RecipientsActive, not recruitingNCT07430683Phase 4
- Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell TransplantationCompletedNCT07181330
- CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary ImmunodeficiencyActive, not recruitingNCT07015801Not applicable
- Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer TreatmentCompletedNCT06870539
- Evaluation of CMV/EBV-CMI in Haploid HSCTStatus unknownNCT06554197
- Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) StudyWithdrawnNCT06522880
- Non Primary HCMV Infection: Natural History and Immune ResponseActive, not recruitingNCT06337955
- A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without AdjuvantsCompletedNCT06145178Phase 1
- A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and RecipientsWithdrawnNCT06133010Phase 2
- A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital CytomegalovirusCompletedNCT06118515Phase 1
- Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant RecipientsActive, not recruitingNCT06066957Phase 2
- Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in ChinaCompletedNCT05789615
- Diagnosis of Congenital Cytomegalovirus Infection in Newborn With Particular RiskCompletedNCT05754879
- Casting Light on HOst-cytomegaloviRUs Interaction in Solid Organ TransplantationActive, not recruitingNCT05701228
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Active, not recruitingNCT05683457Phase 2
- Congenital Cytomegalovirus: Prevalence in Buenos Aires City (cCMV Prevalence)Status unknownNCT05630898
- A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationWithdrawnNCT05589844Phase 1
- A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and CanadaCompletedNCT05576805
- A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and CanadaCompletedNCT05571137
- Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant StudyActive, not recruitingNCT05532540
- The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 PatientsCompletedNCT05419206
- A Study of Modified mRNA Vaccines in Healthy AdultsCompletedNCT05397223Phase 1
- Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.TerminatedNCT05370976Phase 2
- Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERACompletedNCT05315882
- Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)TerminatedNCT05170269Phase 3
- CMV-TCR-T Cells for CMV Infection After Allogenic HSCTStatus unknownNCT05140187Phase 1
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647CompletedNCT05105048Phase 1
- Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer PatientsTerminatedNCT05101213Phase 1
- Study on Correlation Between Cytomegalovirus and Ocular Myasthenia GravisStatus unknownNCT05091177
- CMV-TCR-T Cells for Refractory CMV Infection After HSCTStatus unknownNCT05089838Phase 1
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeTerminatedNCT05085366Phase 3
- A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineCompletedNCT04975893Phase 2
- Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune ResponseWithdrawnNCT04936971Phase 4
- Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV InfectionCompletedNCT04934527Phase 2
- Comparison of Safety and Efficacy of de Novo EverolimusCompletedNCT04906304Not applicable
- A Phase 2a Study of IV BCV in Subjects With Adenovirus InfectionCompletedNCT04706923Phase 2
- AntiCMV molécules Monitoring in Real-life in Stem Cell RecipientsCompletedNCT04690933
- Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconversion During Pregnancy,CompletedNCT04658810
- Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in PregnancyCompletedNCT04615715Not applicable
- Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation RecipientsCompletedNCT04478474
- Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent IndividualsCompletedNCT04392297
- CMV Infection and Immune Intervention After TransplantationStatus unknownNCT04320303Not applicable
- Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer TherapyStatus unknownNCT04280380
- Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells ResponseStatus unknownNCT04278547Phase 4
- Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus InfectionStatus unknownNCT04225780Phase 1/2
- Inflammation and Co-Infections in D²EFTWithdrawnNCT04183738Phase 4
- CMV-TCR-T Cells for CM Virus Infection After HSCTCompletedNCT04153279Phase 1
- Cytomegalovirus Infection in Patients With HIV-1 InfectionCompletedNCT04067869Phase 3
- Epidemiology and Prevention of Congenital HCMV in Immune Mothers. Congenital HCMV Infection LombardyStatus unknownNCT03973359Not applicable
- A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant RecipientsTerminatedNCT03950414Phase 1
- CMV T Cell Immunity in Pediatric Solid Organ Transplant RecipientsCompletedNCT03924219
- Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control PatientsCompletedNCT03916497
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaCompletedNCT03915366Phase 2/3
- Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMVStatus unknownNCT03858907
- Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T CellsTerminatedNCT03798301Phase 1
- Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.CompletedNCT03699254Phase 3
- (Val)Ganciclovir TDM in Transplant RecipientsStatus unknownNCT03698435
- Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic ValganciclovirCompletedNCT03631316Not applicable
- Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant RecipientStatus unknownNCT03576014Phase 1
- Reducing Acquisition of CMV Through Antenatal EducationCompletedNCT03511274Not applicable
- Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell TransplantationActive, not recruitingNCT03475212Phase 1/2
- Cytomegalovirus Infection in Steroid-refractory Ulcerative ColitisStatus unknownNCT03467841
- Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy AdultsCompletedNCT03382405Phase 1
- A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV InfectionWithdrawnNCT03369912Phase 2
- Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.CompletedNCT03339661Phase 2
- PREDICT Cytomegalovirus (CMV)CompletedNCT03300882
- Relevance of Gastric Aspirate in HCMV DetectionTerminatedNCT03262194
- Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive RecipientsStatus unknownNCT03210090
- Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV InfectionStatus unknownNCT03188679Not applicable
- Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic InfectionsTerminatedNCT03159364Phase 1/2
- Role of Endothelial Biomarkers in Patients With Coronary Artery DiseaseStatus unknownNCT03146208
- CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.CompletedNCT03067155Phase 2
- CMV-CTL for the Treatment of CMV Infection After HSCTCompletedNCT03004261Phase 4
- Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCTSuspendedNCT02988258Phase 1
- Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post TransplantationCompletedNCT02985775Phase 1/2
- The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese PopulationStatus unknownNCT02973464